Articles by Zachary Bessette
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Clarity released updated data on COBRA, confirming that 64Cu-SAR-bisPSMA leads to higher detection of lesions in BCR.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Initial data from the COBRA trial confirm that 64Cu-SAR-bisPSMA is safe and “highly” effective in detecting BCR PC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Improved outcomes in patients with previously untreated la/mUC after EV/pembro, even in poor prognosis patient subgroups.
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
A retrospective study of patients with accRCC offers understandings of the role of tivozanib in the current RCC landscape.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Prolonged avelumab first-line maintenance treatment is associated with stable PROs for those with aUC.
An early-stage trial highlights the antitumor activity from erdafitinib plus EV for mUC with FGFR2/3 genetic alterations.
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.